Youmobs

Antibody Production Market to Grow to $58.35 Billion by 2031

Meticulous Research®, a prominent market research organization, has released a comprehensive report titled “Antibody Production Market by Product [Bioreactors (Single Use, Reusable), Chromatography, Filtration, Cell Lines, Media, Buffers, Resins], Antibody [Monoclonal, Polyclonal], Source [Mice, Rabbit], Process [Downstream, Upstream] – Global Forecast to 2031.”

 

The report forecasts that the antibody production market will experience robust growth, achieving a CAGR of 11.4% from 2024 and reaching $58.35 billion by 2031. Key drivers of this growth include the escalating demand for targeted antibodies, increased R&D investment from pharmaceutical and biotech firms, and the rising incidence of cancer and autoimmune disorders. Additionally, advancements in bioprocessing technologies and the growing application of immunoassays are expected to significantly boost market expansion. However, challenges such as high production costs and stringent regulatory requirements may impede growth.

 

Emerging markets, particularly in developing countries, present substantial opportunities, driven by the increasing use of antibodies in clinical research and the heightened prevalence of infectious diseases. Nevertheless, the complexity of monoclonal antibodies continues to challenge market participants.

 

Major players in the market, including Thermo Fisher Scientific Inc. (U.S.), Merck KgaA (Germany), and Danaher Corporation (U.S.), are pivotal in driving market innovation and meeting the increasing global demand.

 

The market is categorized by product, antibody type, source, process, and end-user. The instruments segment, which comprises bioreactors and chromatography systems, is expected to lead the market in 2024, fueled by the need for mass production and the refinement of antibodies for therapeutic uses. Monoclonal antibodies, in particular, are anticipated to witness the highest growth rate due to their expanding role in treating complex diseases like cancer.

 

Mice are projected to continue dominating the source segment, owing to their affordability, ease of production, and well-established use in genetic engineering. In terms of processing, downstream methods are likely to capture the largest market share, given their critical role in the purification and recovery of antibodies.

 

The pharmaceutical and biotechnology sectors are expected to emerge as the fastest-growing end users, driven by increased R&D activities, the expansion of antibody production facilities, and the ongoing development of new antibody-based therapies.

 

Regionally, North America is poised to lead the antibody production market, followed closely by Europe and Asia-Pacific. This leadership is attributed to advanced technological infrastructure, significant R&D investments, and a high burden of chronic diseases that necessitate innovative biologic therapies.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5769

 

Key Questions Answered in the Report:

 

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

Exit mobile version